HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: Role of protease inhibitor exposure

被引：26

作者：

Hurwitz B.E. ^{[1
,2
,3
,7
]}

Klimas N.G. ^{[1
,5
]}

Llabre M.M. ^{[1
,2
]}

Maher K.J. ^{[1
,5
]}

Skyler J.S. ^{[1
,3
]}

Bilsker M.S. ^{[1
,4
]}

McPherson-Baker S. ^{[1
,5
]}

Lawrence P.J. ^{[1
]}

LaPerriere A.R. ^{[1
,6
]}

Greeson J.M. ^{[2
]}

Klaus J.R. ^{[2
]}

Lawrence R. ^{[1
]}

Schneiderman N. ^{[1
,2
,3
,6
]}

机构：

[1] Behavioral Medicine Research Center, University of Miami, Miami, FL

[2] Department of Psychology, University of Miami, Coral Cables, FL

[3] Div. of Endocrinology and Metabolism, University of Miami, Miami, FL

[4] Division of Cardiology, Department of Medicine, University of Miami, Miami, FL

[5] Dept. of Microbiology and Immunology, University of Miami, Miami, FL

[6] Dept. of Psychiat. and Behav. Sci., University of Miami, Miami, FL

[7] Behavioral Medicine Research Center, 200 BMRC, c/o VA Medical Center, Miami, FL 33125

来源：

Cardiovascular Toxicology | 2004年 / 4卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Coronary heart disease risk; HAART; HIV/AIDS; Inflammation; Metabolic syndrome X; Oxidative stress;

D O I：

10.1385/CT:4:3:303

中图分类号：

学科分类号：

摘要：

Differences on measures of metabolic syndrome X and coronary heart disease (CHD) risk, as well as potential pathophysiological mediators, inflammation, and oxidative stress, were examined as a function of HIV serostatus and highly active antiretroviral therapy (HAART) regimen with and without protease inhibitors (Pls). Data from 164 men and women, aged 18 to 55 yr, were used to compare 82 HlV+ subjects who were free of hepatitis C virus and were on a stable HAART regimen for ≥6 mo, with 82 seronegative subjects matched on age, sex, body mass index, and ethnicity. For the HlV+ subjects, after controlling for diabetes status and HIV disease progression, PI exposure was associated with greater oxidative stress, triglyceridemia, and lipidemia than it was for non-PI-exposed HIV+ subjects, and the risk of a future myocardial infarction was up to 56% greater in PI-exposed than in non-PI-exposed subjects and 129% greater than in controls. Although it is likely that the greatest proportion of CHD risk in the HIV+ subjects may be accounted for by pathological conditions linked to HIV infection in interaction with mediating processes such as inflammation, central obesity, and dyslipidemia, which was greater than in controls, it appears that PI medications may exacerbate oxidative stress and hypertriglyceridemia to enhance this risk.

引用

页码：303 / 315

页数：12

共 70 条

[1]

Vigoureux C., Gharakhanian S., Salhi Y., Nguyen T.H., Adda N., Rozenbaum W., Et al., Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease, Diabetes Metab., 25, pp. 383-392, (1999)

[2]

John M., Nolan D., Mallal S., Antiretroviral therapy and the lipodystrophy syndrome, Antivir. Ther., 6, pp. 9-20, (2001)

[3]

Nolan D., Mallal S., Getting to the HAART of insulin resistance, AIDS, 15, pp. 2037-2041, (2001)

[4]

Reaven G.M., Pathophysiology of insulin resistance in human disease, Physiol. Rev., 75, pp. 473-486, (1995)

[5]

Schneiderman N., Skyler J.S., Insulin metabolism, sympathetic nervous system regulation, and coronary heart disease prevention, Behavioral Medicine Approaches to Cardiovascular Disease Prevention, pp. 105-133, (1996)

[6]

Dube M.P., Sprecher D., Henry W.K., Aberg J.A., Torriani F.J., Hodis H.N., Et al., Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group, Clin. Infect. Dis., 31, pp. 1216-1224, (2000)

[7]

Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., Et al., Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy, Clin. Infect. Dis., 32, pp. 130-139, (2001)

[8]

Mynarcik D.C., McNurlan M.A., Steigbigel R.T., Fuhrer J., Gelato M.C., Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy, J. Acquir. Immune Defic. Syndr., 25, pp. 312-321, (2000)

[9]

Ross R., Atherosclerosis - An inflammatory disease, N. Engl. J. Med., 340, pp. 115-126, (1999)

[10]

Dinarello C.A., Interleukin-1 and its biologically related cytokines, Adv. Immunol., 44, pp. 153-205, (1989)

← 1 2 3 4 5 6 7 →